Tags

Type your tag names separated by a space and hit enter

COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID.
Mult Scler Relat Disord. 2020 Aug 10; 46:102447.MS

Abstract

BACKGROUND

The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a novel disease that has spread abruptly over the world, allowing the development of countermeasures an urgent global priority. It has been speculated that elder people and patient with comorbidities may be at risk of developing complication. On the other hand, it has been seen that immunosuppressed patients could develop a mild presentation of the disease. Based on this hypothesis, several immunosuppressant agents are currently being tested as potential treatment for coronavirus 2019 (COVID-19).

METHODS

report a patient treated with alemtuzumab (Humanized monoclonal antibody against the lymphocyte and monocyte surface antigen CD52, which depletes B and T cells) (Thompson et al., 2018) for recurrent remittent multiple sclerosis (RRMS) who developed mild COVID-19.

RESULTS

Despite complete B and T cell depletion, patient symptoms abated few days with no need for hospitalization due to COVID-19 and no clinical evidence of disease activation regarding her MS.

DISCUSSION

This report shows that MS patients with mild depletion of B and T cells can mount an antiviral response against COVID-19 and produce IgG.

Authors+Show Affiliations

Universidad del Desarrollo-Clínica Alemana, Santiago, Chile.Department of Neurology, Clínica Alemana, Santiago, Av Vitacura 5951, Vitacura, Santiago, Chile. Electronic address: lornag@gmail.com.

Pub Type(s)

Letter

Language

eng

PubMed ID

32835901

Citation

Fiorella, Celsi, and Galleguillos Lorna. "COVID-19 in a Multiple Sclerosis (MS) Patient Treated With Alemtuzumab: Insight to the Immune Response After COVID." Multiple Sclerosis and Related Disorders, vol. 46, 2020, p. 102447.
Fiorella C, Lorna G. COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID. Mult Scler Relat Disord. 2020;46:102447.
Fiorella, C., & Lorna, G. (2020). COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID. Multiple Sclerosis and Related Disorders, 46, 102447. https://doi.org/10.1016/j.msard.2020.102447
Fiorella C, Lorna G. COVID-19 in a Multiple Sclerosis (MS) Patient Treated With Alemtuzumab: Insight to the Immune Response After COVID. Mult Scler Relat Disord. 2020 Aug 10;46:102447. PubMed PMID: 32835901.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID. AU - Fiorella,Celsi, AU - Lorna,Galleguillos, Y1 - 2020/08/10/ PY - 2020/06/26/received PY - 2020/08/06/revised PY - 2020/08/09/accepted PY - 2020/8/25/pubmed PY - 2020/8/25/medline PY - 2020/8/25/entrez KW - Alemtuzumab KW - Coronavirus 2019 KW - Immunity KW - Multiple sclerosis KW - Reinfection SP - 102447 EP - 102447 JF - Multiple sclerosis and related disorders JO - Mult Scler Relat Disord VL - 46 N2 - BACKGROUND: The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a novel disease that has spread abruptly over the world, allowing the development of countermeasures an urgent global priority. It has been speculated that elder people and patient with comorbidities may be at risk of developing complication. On the other hand, it has been seen that immunosuppressed patients could develop a mild presentation of the disease. Based on this hypothesis, several immunosuppressant agents are currently being tested as potential treatment for coronavirus 2019 (COVID-19). METHODS: report a patient treated with alemtuzumab (Humanized monoclonal antibody against the lymphocyte and monocyte surface antigen CD52, which depletes B and T cells) (Thompson et al., 2018) for recurrent remittent multiple sclerosis (RRMS) who developed mild COVID-19. RESULTS: Despite complete B and T cell depletion, patient symptoms abated few days with no need for hospitalization due to COVID-19 and no clinical evidence of disease activation regarding her MS. DISCUSSION: This report shows that MS patients with mild depletion of B and T cells can mount an antiviral response against COVID-19 and produce IgG. SN - 2211-0356 UR - https://www.unboundmedicine.com/medline/citation/32835901/COVID_19_in_a_multiple_sclerosis__MS__patient_treated_with_alemtuzumab:_Insight_to_the_immune_response_after_COVID_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2211-0348(20)30522-8 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.